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ABSTRACT 
With the aim of identifying a fluorinated bile acid derivative that could be used as [18F]-labeled 
Positron Emission Tomography (PET) tracer for imaging the in vivo functioning of liver transporter 
proteins, and particularly of OATP1B1, three fluorinated bile acid triazole derivatives of cholic, 
deoxycholic and lithocholic acid (CATD, DCATD and LCATD 4a-c, respectively) were synthesized and 
labeled with tritium. In vitro transport properties were studied with cell-based assays to identify the 
best substrate for OATP1B1. In addition, the lead compound, LCATD (4c), was tested as a substrate of 
other liver uptake transporters OATP1B3, NTCP and efflux transporter BSEP to evaluate its specificity 
of liver transport. The results suggest that 4c is a good substrate of OATP1B1 and NTCP, whereas it is 
a poor substrate of OATP1B3. The efflux transporter BSEP also appears to be involved in the excretion 
of 4c from hepatocytes. The automated radiosynthesis of [18F]-4c was accomplished in a multi-GBq 
scale and a pilot imaging experiment in a wild type rat was performed after i.v. administration to 
assess the biodistribution and clearance of the tracer. PET imaging revealed that radioactivity was 
primarily located in the liver (tmax = 75 seconds) and cleared exclusively through the bile, thus allowing 
to image the hepatobiliary excretion of bile acids in the animal model. These findings suggest that 
[18F]-LCATD 4c is a promising PET probe for the evaluation of hepatic transporters OATP1B1, NTCP and 
BSEP activity with potential for studying drug-drug interactions and drug-induced toxicity involving 
these transporters.  
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1. INTRODUCTION 
Hepatic transporter proteins mediate the transport of many molecules through the 
hepatocyte, from the blood stream into the bile. Among the membrane transporters expressed on the 
basolateral membrane of hepatocytes, OATP1B1, OATP1B3 and NTCP play an important role in the 
uptake of both xenobiotics - such as drugs and their metabolites - and endogenous compounds - such 
as bile acids and bilirubin.1-3 Alteration of the functionality of these transporters may affect 
distribution and clearance of drugs and cause accumulation of toxic endogenous compounds in the 
blood.4 Canalicular transporters such as MATE1, MRP2, BCRP, BSEP and P-gp (MDR1/3), expressed on 
the apical membrane of hepatocytes, mediate the biliary excretion of drugs, drug metabolites and 
endogenous compounds. Inhibition of the canalicular efflux transporters can result in the 
accumulation of toxic metabolites in the hepatocyte, causing drug induced liver disease.5 Among the 
uptake transporters, the organic anion transporter polypeptide OATP1B1 (SLCO1B1, also called OATP-
C) is a particularly important liver specific transporter involved in the hepatic uptake of a wide range 
of clinically relevant drugs.1,6 According to recent studies on the absolute quantitative determination 
of the amount of transporters in the human liver, OATP1B1 is the most abundant uptake transporter.7 
OATP1B1 downregulation, inhibition or genetic polymorphism may lead to inter-individual 
pharmacokinetic alterations and potential drug-drug interactions (DDIs).8 Conversely, the sodium 
taurocholate co-transporting polypeptide NTCP, (SLC10A1), appears to be involved in the uptake of a 
relatively small number of clinically used drugs, but inhibition of NTCP can be a contributing factor to 
DDIs and a reduced NTCP activity or expression can result in a depressed bile acid uptake leading to 
cholestasis and hyperbilirubinemia.3,9,10 On the other hand, the efflux transporter BSEP (bile salt export 
pump, ABCB11), mediates the excretion of bile acid salts from the apical membrane of hepatocytes to 
the bile canaliculi.9,11 Reduced activity of this transporter can be involved in drug induced liver injury 
caused by the accumulation of toxic bile acids in hepatocytes.12-14 Imaging of hepatic transporters 
activity has produced interesting data that contributed to increase the understanding of DDI’s 
pharmacokinetics and proved the role of membrane transporters in drug distribution and disposition 
of some important clinically used drugs. Recently, review articles have been published which provide 
extensive information on general aspects, such as ideal criteria of Positron Emission 
Tomography/Computed Tomography (PET/CT) probes, design of hepato-selective PET probes, case 
studies, strengths and weaknesses of PET in imaging of transporters.15 PET tracers which are actively 
transported across cellular membranes can be used as probes to study membrane transport in vivo 
by imaging the tracer’s uptake. In principle, any transport inhibition of the tracer would alter its in vivo 
distribution, which in turn could be used to determine the DDI potential of investigational drugs 
capable of inhibiting the tracer’s transport pathways mediated by the transporter protein(s) involved. 
Bile acids – which are endogenous compounds synthesized in the liver as final products of cholesterol 
metabolism and excreted in the bile of vertebrates – are obvious substrates of these important 
transporters, and have been extensively employed as probe compounds to study physiological and 
pathological conditions related to the hepatobiliary transport.16-19  
In this paper we report the design and synthesis of three fluorinated bile acid derivatives 4a-c as 
prospective PET tracers for the imaging of OATP1B1/1B3, NTCP and BSEP activity in vivo. These 
compounds were labeled with tritium and assayed for in vitro transport properties. Based on the in 
vitro tests results, the lead compound LCATD (4c) was selected as candidate PET tracer and a fully 
automated radiosynthesis of [18F]-4c, suitable for producing the tracer in multi-GBq scale, was 
developed. Finally, a pilot imaging experiment was performed in a rat to prove that the PET tracer 
[18F]-4c is hepatocyte-directed and excreted only through the bile. 
2. RESULTS 
2.1 Synthesis of unlabeled and tritiated bile acid derivatives.  
The “cold” compounds CATD, DCATD and LCATD (4a-c) were synthesized respectively from cholic acid 
1a, deoxycholic acid 1b and lithocholic acid 1c, which were reacted with racemic propargyl-glycine 
methyl ester and HATU in the presence of diisopropylethylamine. Propargyl-glycine-conjugated bile 
acids 2a-c were isolated in good yields (>82%) as diastereomeric mixtures by flash column 
chromatography (FCC). Compounds 2a-c were then reacted with 1-azido-4-fluorobutane (obtained in 
turn from 1-bromo-4-fluorobutane and sodium azide in DMF) in the copper-mediated alkyne–azide 
cycloaddition (CuAAC) to give triazoles 3a-c in high yields and with complete regiocontrol.20 Ester 
function deprotection of 3a-c with 2M KOH in methanol solution gave quantitative yield of bile acid-
triazole derivatives 4a-c as inseparable mixtures of two diasteroisomers (Scheme 1). Unsuccessful 
attempts were made for separating the diastereomers by flash chromatography. 
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Scheme 1. Reagents and conditions: i): propargylglycine methyl ester, HATU, DIPEA, DCM, r.t. 3 hr; ii): 1-azido-4-
fluorobutane, CuSO4, Sodium Ascorbate in t-BuOH/H2O, r.t. 24 h; iii): 2M aqueous KOH in methanol, r.t. 15 min. 
 
Tritium labelling was achieved from the corresponding iodoalkynes 5a-c as previously described for 
[3H]-CATD 4a,21 affording the labeled compounds in >99.8 % radiochemical purity and specific 
activity of 19.5-23.2 Ci mmol-1 (Scheme 2).  
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Scheme 2. Reagents and conditions:i) N-iodomorpholine-hydrogen iodide, CuI, THF, r.t. 1 h; 1-azido-4-fluorobutane, CuI, 
TEA, r.t. 24 h; ii) T2, Pd/C, TEA, EtOH, r.t., 1.5 h; iii) NaOH 5M, H2O, r.t 2 hr (radiochemical purity before purification 94%). 
 
2.2. In Vitro uptake of compounds [3H]-4a-c in HEK293 OATPB1 cells 
Cellular uptake of tritium labeled compounds [3H]-4a-c was measured using monolayer cultures of 
human embryonic kidney cells (HEK293) transfected in order to overexpress the OATP1B1 transporter 
and HECK293-MOCK cells, e.g. the same human embryonic kidney cells but transfected with an empty 
vector, used as negative control.  
[3H]-4a-c (0.05 μM) uptake was found to be higher in HEK293-OATP1B1 cells than in HEK293-MOCK 
transfected cells. However, while the uptake of [3H]-4a in HEK293-OATP1B1 cells reached the plateau 
after the first four minutes of incubation, the uptake of [3H]-4b and [3H]-4c in HEK293-OATP1B1 cells 
increased linearly until the last investigated time point, i.e. sixteen minutes. The amount of [3H]-4a 
taken up into HEK293-OATP1B1 cells was about fifteen times lower than the amount of [3H]-4b and 
[3H]-4c (Fig 1). 
 
Figure 1. Time dependent uptake of probe substrates [3H]-4a-c in HEK293-OATP1B1 and HEK293-MOCK  transfected cells 
(0.05 µM, n = 3). 
The uptake of [3H]-4a was significantly higher (p < 0.05) in HEK293-OATP1B1 cells than in HEK293-
MOCK transfected cells at all the concentrations studied (Fig. 2). Uptake ratio for [3H]-4a was between 
2.0 and 1.3. The uptake of both [3H]-4b and [3H]-4c was also significantly higher (p < 0.01) in HEK293-
OATP1B1 cells than in HEK293-MOCK cells, and for the lower concentration studied (1 and 10 μM) the 
difference was significant (p < 0.001). Uptake ratios were found to be between 6.5 and 11.8 for [3H]-
4b and between 2.0 and 7.3 for [3H]-4c.  
  
Figure 2. Concentration dependent uptake and uptake ratios (± standard error) of probe compounds in HEK293-OATP1B1 
and HEK293-MOCK transfected cell lines. Data of concentration dependent uptakeis expressed as mean ± SD (n=3); *** (p < 
0.001); ** (p < 0.01); * (p < 0.05).Error bars in the uptake ratio represent the uncertainty in the data point calculated 
according to equation 5.   
 
The net OATP1B1-mediated substrate transport (UOATP1B1) was found to be saturable for 4c and it 
could be described with a Michaelis–Menten equation (Fig. 3C), whereas full saturation could not be 
reached for 4a,b (Fig. 3A,B). For 4c the apparent Km and Vmax, determined by plotting UOATP1B1 (pmol 
min−1 mg−1) against substrate concentration, are reported in Table 1. 
 
 
Figure 3. Kinetics of OATP1B1-mediated uptake of substrates (A) CATD 4a (B) DCATD 4b (C) LCATD 4c. Data is expressed as 
mean ± SD (n = 3) and best fit curve is shown. 
(A) (B) (C)
 The uptake of [3H]-4a-c (0.05 μM) was inhibited by rifamycin SV, a reference inhibitor of OATP1B1, at 
concentrations lower than 1 µM. However, the inhibition curve obtained for [3H]-4a was poorly 
defined due to the small inhibition window and hence it was impossible to calculate an IC50 value for 
rifamycin SV employing [3H]-4a as probe substrate. Conversely, using [3H]-4b,c as probe substrates, 
IC50 values for rifamycin SV could be obtained (0.13 and 0.40 µM respectively, see also Table 1 and Fig. 
4).  
 
 
Figure 4. Concentration dependent OATP1B1-mediated uptake inhibition of (A) DCATD (4b) (B) LCATD (4c) by rifamycin SV. 
Data is expressed as mean ± SD (n=3) and best fit is shown. The IC50 of CATD (4a) uptake inhibition by rifamycin SV could not 
be experimentally determined because of lack of full inhibition window since 4a is not a good substrate of OATP1B1. 
Concentrations of Rifamycin were 100, 10, 1, 0.1, 0.01, 0.001 μM, concentration of 4a-c = 0.05 µM. 
 
Values of OATP1B1-intrinsic clearance (or intrinsic capacity) CLint, OATP1B1 and passive diffusion clearance 
CLdiff obtained for 4c are reported in Table 1 along with those obtained in the same cells and - as 
reported previously by our group6 - for some well-known OATP1B1 probe compounds: estradiol-17-
β-glucuronide, pravastatin and pitavastatin. Since the OATP1B1 mediated transport of 4c is similar to 
that of these OATP1B1 probes (Table 1), this compound was selected as potential PET tracer, and its 
transport properties were further investigated. 
 
Probe 
compound 
Km (μM) 
 
Vmax (pmol 
min−1 mg−1) 
IC50 
Rifamycin 
SV (μM) 
CLint, OATP1B1 
(µL min-1 
mg-1) 
CLdiff  
(µL min-1 
mg-1) 
Ratio 
(CLint, OATP1B1 
/ CLdiff) 
 
[3H]-4c (LCATD) 10 (6) 581 (101) 0.40 (0.05) 58 0.64 91 
Estradiol-17-β-
glucuronide 
5.5 (1.3) 436 (29) 0.32 (0.05) 79 2.6 30 
Pravastatin 29 (2.7) 277 (7) 0.14 (0.08) 9.6 1.9 5 
Pitavastatin 
1.3 
(0.29) 
373 (21) 0.27 (0.01) 287 13.6 21 
 
Table 1. Mean apparent kinetic parameters (and standard errors) for 4c in OATP1B1 substrate and inhibition assay 
obtained in this study compared with well-known OATP1B1 substrates as reported earlier in the same system.6 
 
2.3. Uptake of [3H]-LCATD (4c) in HEK293-OATP1B3 and CHO-NTCP cells  
(A) (B)
The uptake of [3H]-4c was also studied in HEK293-OATP1B3 and NTCP expressing CHO-cells. In an 
HEK293-OATP1B3 cell line the uptake of [3H]-4c (0.05 μM) was higher than in the HEK293-MOCK 
transfected cell line up to 4 minutes of incubation. However, at 4 and 8 minutes of incubation the 
accumulation in HEK293-OATP1B3 was found not statistically relevant (Fig. 5A). Uptake ratios were 
between 2.0 and 2.4 (at concentrations 10 and 100 μM respectively, Fig. 5B). An attempt to estimate 
Km by measuring the OATP1B3-mediated uptake failed as the saturation of the transporter was not 
reached at the highest concentration studied (100 µM). In CHO-NTCP cells the uptake of [3H]-4c (0.05 
μM) was found to be higher than in the control cell line and linear between 1 and 10 minutes of 
incubation and higher than in CHO-parental cell line at any time (Fig. 6). Uptake ratios were between 
4 and 32. The net NTCP-mediated substrate transport (UNTCP) was found to be saturable and followed 
a Michaelis–Menten kinetic (Fig. 7A). Apparent Km and Vmax, determined by plotting UNTCP (pmol min−1 
mg−1) against substrate concentration were found to be 49 μM and 2035 pmol/min/mg, respectively. 
 
Figure 5. A) Time dependent uptake of [3H]-4c in HEK293-OATP1B3 and HEK293-MOCK cells. B) Uptake of [3H]-4c (10-100 
µM) in HEK293-OATP1B3 and HEK293-MOCK cells. Data is expressed as mean ± SD (n=3); *** (p < 0.001); ** (p < 0.01). 
 
 
Figure 6. Time dependent uptake of [3H]-4c in CHO-NTCP and CHO-MOCK cells.  
 
2.4. Uptake of [3H]-LCATD (4c) in BSEP inverted vesicles  
Transport of LCATD (4c) was determined in membrane vesicles transfected with BSEP transporter in 
the presence of ATP (total transport) and AMP (passive transport) over a concentration range 10-300 
µM. The ATP dependent transport was determined by deducting the transport in the presence of 
ATP to that in the presence of AMP and this reflected the BSEP mediate transporter activity 
(pmol/min/mg). Compound 4c exhibited concentration dependent BSEP mediated transport in BSEP 
transfected membrane vesicles (Fig. 7B). 
 
 
Figure 7. Kinetics of LCATD by bile transporters (A) NTCP-mediated uptake (B) BSEP-mediated efflux. Data is expressed as 
mean ± SD (n = 3) and best fit curve is shown. 
 
2.5 Radiosynthesis of [18F]-LCATD-4c 
Compound 2c was acylated in >98% yields with acetic anhydride in anhydrous pyridine to give the 
alkyne 6 which was reacted with 4-azidobutanol, copper sulphate and sodium ascorbate in a 
water/tert-butanol mixture (1:2) to give 7 in 90% yields. The mesylation was carried out in anhydrous 
dichloromethane in the presence of freshly distilled triethylamine and mesyl chloride, to give the 
radiofluorination precursor 8.  
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Scheme 3. Reagents and conditions: i) Ac2O, in Py, r.t., 3 h; ii) 4-azidobutanol, CuSO4, sodium ascorbate in tBuOH/H2O (2:1), 
r.t., 24h; iii) MsCl, TEA, in DCM, r.t. 4-12 h; iv) [18F]-KF, K222, K2HPO4, ACN, 90 °C, 15 min; v) NaOH 2M, 40 °C, 10 min, HPLC 
purification, radiochemical yield 25 ± 5 % (n = 5) decay corrected. 
Finally, automated [18F]-radiofluorination of 8 using the [18F]KF-K222 dry complex in a modular reactor, 
followed by hydrolysis of methyl ester and acetate functions with NaOH, afforded the tracer [18F]-4c 
in 25 ± 5 % (n = 5) decay corrected radiochemical yield, as a mixture of two epimers at the α-amino 
acid carbon. The total radiosynthesis, purification and formulation time was about 90 minutes. 
 
2.6. Imaging results  
A pilot imaging experiment with [18F]-LCATD ([18F]-4c) in a wild type rat was performed for assessing 
biodistribution and clearance of the PET tracer. The radioactivity distribution (as coronal maximum 
intensity projections) at 1, 2, 5, 10, 20, 25 minutes after intravenous administration of [18F]-LCATD in 
a representative control rat is shown in Fig. 8 (PET-CT). The radioactivity was primarily located in the 
liver with no obvious uptake in the kidneys or other organs in the abdominal region. The liver uptake 
and biliary excretion of radioactivity through the biliary duct was clearly visible after 1-2 minutes post-
injection. At 20 minutes the radioactivity was localised mainly in the intestinal region while almost no 
signal was visible in the liver.  
 
 
Figure 8. Images obtained for a representative control rat. At 1 min only the liver is visible. At 2 min the bile duct is clearly 
visible. From 5 to 25 minutes the intestine is visible because of the presence of the bile containing the radioactive tracer. 
Time-activity curves (TAC) for the liver, blood and intestine are shown in Fig. 9. The activity in the 
blood, deduced from the activity of the region of interest (ROI) corresponding to the abdominal aorta, 
rapidly decreased after 15 seconds from the injection to less than 1% after 10 min. The TAC in the liver 
increased linearly for the first 75 seconds post-injection, reached a peak corresponding to 12.4% of 
the injected dose at 165 seconds and then exponentially decreased to 1% of the injected dose after 
27 minutes. The TAC for the intestine ROI reached the maximum activity (29.5 % of the injected dose) 
8.75 minutes after the liver peak activity, at 11.5 minutes from the injection. After this time the activity 
measured in the intestine appeared to decrease, probably because of the bile flow to the lower 
intestine region, which was not entirely covered by the field of view of the PET scan. 
 
Figure 9. Time-activity curves for the three ROIs blood, liver and intestine after i.v. administration to SD rat (n=1). Inset: 
time-activity curves from 0 to 5 minutes. 
Although a detailed analysis of the metabolic fate of [18F]-4c is not yet available, the expected 
metabolism for compound 4c may be similar to that of lithocholic acid: in rats hydroxylation at the 
position 3, 6 and 7 may occur, as well as glucuronidation of the hydroxyl group in position 3,24 while 
in humans, oxidation of the hydroxyl group to ketone and hydroxylation of positions 6 and 7 may be 
possible (3-ketocholanoic acid is the major in vitro human hepatic microsomal metabolite of 
lithocholic acid).25 The labelling position is however stable, as no uptake of [18F]-fluoride in the bone 
tissue was observed in the PET-CT scan.   
 
3. DISCUSSION AND CONCLUSION 
In this study we synthesized three fluorinated derivatives of endogenous bile acids 4a-c as candidate 
probes for imaging hepatic transporters activity (Fig. 10). The current project was focussed primarily 
on characterizing the in vitro transport of 4a-c by OATP1B1/1B3 because of their well-understood role 
in clinical DDIs,2 but the possibility of 4a-c being transported by other uptake transporters (for 
example, OATP2B1, OATP1A2, OAT2, OAT7) cannot be excluded. In addition to OATP1B1/1B3, bile salt 
transporters (NTCP/BSEP) were also studied because of the close structural similarity of 4a-c to bile 
salts and hence the possibility of NTCP/BSEP being involved in their transport.  
 
 
Fig. 10. Transporter proteins in the hepatocyte relevant to this study. 
 
The three compounds 4a-c share the same carbon-backbone but have different numbers of OH groups 
on the bile acid scaffold: this affects the lipophilicity of the compounds as well as their number of 
donor/acceptor hydrogen bonds (see Table 2). The bile acid derivatives 4a-c were readily prepared 
from commercial bile acids through a short synthetic route which also allowed the synthesis of tritium 
labeled compounds [3H]-4a-c used for in vitro assays.  
The utility of PET in the imaging of hepatic transporters has been demonstrated in recent years by a 
number of publications in which several [11C]-labeled PET tracers have been proposed. For example, 
[11C]-cholylsarcosine has been successfully employed to image the biliary excretion in pigs, with 
potential applications in the study of pathophysiological conditions of the liver such as inherited 
cholestasis , acquired liver disease, acute hepatitis, primary biliary cirrhosis, post-transplantation liver 
dysfunction, and biliary obstruction.14,26 However, only [11C]-labeled PET tracers have been developed 
so far to study hepatic membrane transporters, thus limiting the access to this valuable technology to 
PET centres with a cyclotron on site.27 In addition, the higher activity achievable for production run 
and the longer half-lives of [18F]-labeled tracers represent a clear advantage over [11C]-tracers for both 
pre-clinical and clinical PET imaging. 
In order to identify and characterize the transporters involved in the hepatocyte uptake of the 
fluorinated bile acid derivatives 4a-c, in vitro assays were performed using the tritium labeled versions 
[3H]-4a-c. Because OATP1B1 is considered responsible for the hepatic uptake of several endogenous 
and exogenous compounds, we first tested our potential probes as substrates for this transporter. The 
assays demonstrated that compounds 4a-c are substrates of OATP1B1, as the uptake ratios were 
higher than 1. However, the accumulation of [3H]-4a in HEK293-OATP1B1 cells reached a plateau after 
four minutes of incubations, while the uptake of [3H]-4b and [3H]-4c increased linearly with the time 
until the last time point (16 minutes) (Fig. 1 and 2). Values obtained for Km and Vmax indicate that 
OATP1B1 mediated transport of 4c is comparable to that of several prototypical OATP1B1 probes 
(Table 1), therefore it was selected for studying the activity of OATP1B1 in vivo1 (Fig. 3 and Table 1). 
Inhibition experiments with rifamycin SV (Fig. 4) showed that the OATPB1 uptake of all the probe 
compounds was affected by the presence of the inhibitor drug in a dose-dependent manner. However, 
when [3H]-4a CATD was used as a substrate, the IC50 value could not be determined. Using [3H]-4b and 
[3H]-4c as substrates, the expected inhibition curves were obtained, with IC50 values (0.13 and 0.40 
µM respectively) comparable with those obtained using the OATP1B1 reference substrate [3H]-
estradiol 17-β-glucuronide (IC50 = 0.23 ± 0.07 µM) in the same cell system (Table 1).6,22  
OATP1B3 is closely related to OATP1B1 and it is known that bile acids, bilirubin and eicosanoids are 
among the endogenous substrates of both OATP1B3 and OATP1B1:11,28 For this reason compound 4c 
was tested in an OATP1B3 substrate assay (Fig. 5). Even though significant differences were found in 
the uptake rates between the transporter-expressing cells and the control cells, the uptake ratio = 2 
and the incomplete saturation of the transporter at 100 µM suggest that 4c is a poor substrate of 
OATP1B3. In fact literature data about bile acids as substrates for OATP1B3 report Km of 85.3 µM for 
cholic acid, and uptake ratios of 4.9 for prototypical substrates.29 The probe compound 4c showed 
significant linearly time dependent uptake by NTCP-CHO cells, and uptake ratios were 4-32 (Fig. 6). 
The NTCP-mediated transport of 4c in HEK293 cells was saturable and the apparent Km and Vmax were 
49 µM and 2035 pmol/mg/min, respectively (Fig. 7a). Reported value of Km for the prototypical 
substrate taurocholate in NTCP-CHO cells is 8.4 ± 1.3 μM30 which suggests that the introduction of a 
triazole-alkyl chain substituent on the α-carbon of the glycine does not strongly affect the substrate 
recognition by NTCP, albeit it does reduce the affinity.  
The bile acid derivative 4c was also tested as substrate of BSEP, which is the transporter involved in 
the efflux of bile salts from the hepatocyte and into the bile canaliculi (Fig. 7b and 10). Although very 
few drugs are known to be substrates of BSEP, this transporter can be involved in drug induced liver 
injury caused by the accumulation of toxic bile acids in hepatocytes: the inhibition of BSEP by certain 
drugs was in fact correlated to the potential of cholestatic drug induced liver injury.31 In BSEP 
expressing membrane vesicles the derivative 4c exhibited concentration dependent ATP driven active 
transport suggesting that in vivo it might get excreted in bile. Our data indeed suggest that derivative 
4c is a substrate of BSEP, which can play a role in the in vivo excretion of 4c from the hepatocyte into 
the bile.  
Differences in uptake and efflux of compounds 4a-c could be analysed in light of their lipophilicity and 
number of donor/acceptor hydrogen bonds. Estimation of the lipophilicity of the endogenous bile acid 
conjugates and bile acid-triazole derivatives is provided in Table 2.  
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4c 
CLogD = 2.20 
HBD = 3 
HBA = 8 
Table 2. Estimation of the lipophilicity of the bile acid derivatives 4a-c and comparison to that of endogenous bile acids. 
CLogD calculated with StarDrop. HBD = Hydrogen Bond Donor atoms. HBA = Hydrogen Bond Acceptor atoms. 
Compared to the endogenous bile acid conjugates, the corresponding labelled derivatives 4a-c appear 
to be more lipophilic and the introduction of the triazole ring increases the number of hydrogen bond 
acceptor atoms by 3. Difference in physicochemical properties between inhibitors and non-inhibitors 
of OATPs suggests that lipophilicity is positively correlated with the potential for interaction with such 
transporters.32 A substrate pharmacophore for OATP1B1 has been published in 2005 (whose key 
pharmacophore features appear to be two hydrogen bond acceptors at either end of a large 
hydrophobic area)33 however, structural information of the binding site would be required to 
rationalize the structure-activity relationship for the synthesized bile acid derivatives, as all of them 
can easily fit in the proposed pharmacophore.  
The PET tracer version [18F]-4c was synthesized and purified in an automated module which allowed 
the production of multi-GBq amount of radiotracer in good purity and yields for a pilot imaging 
experiment. In order to preliminarily assess the biodistribution of [18F]-4c, in vivo imaging experiments 
were performed in a single wild type rat. Even though there is not a direct orthologue of human 
OATP1B1 in rats and murine OATP1B3 and NTCP transporters have shown different affinity for their 
substrates compared to human transporters,1 the rat model is widely accepted for preclinical 
experiments aimed to assess the involvement of hepatic transporters in the clearance of drugs and 
radiotracers.1,15 The in vivo biodistribution of [18F]-4c was found to be liver-specific, as the tracer 
uptake was selective in the liver and then the tracer was excreted in the bile: no activity was detected 
in the kidneys or urinary bladder (Fig. 8 and Fig. 9). Based on the in vitro tests, the liver uptake and 
excretion of [18F]-4c should be mostly due to the effect of membrane transporter OATP1B1 and NTCP. 
The poor passive permeability of 4c, which is ionized at physiological pH, and the exclusive and fast 
distribution in the liver support this hypothesis. As expected, after being accumulated into the liver, 
the tracer is excreted into the bile via the efflux transporter BSEP, even if we cannot exclude the 
contribution of other efflux transporters such as MATE1, BCRP, MRP2 and PgP. The probe compound 
O
HN
H
H
OHHO
OH H
H
CO2H
H
4c is therefore transported by three of the major clinically relevant transporters involved in drug-drug 
interactions and drug induced liver injury (OATP1B1, NTCP and BSEP). This suggests that [18F]-4c is a 
promising PET tracer to study in vivo the potential for transporters-mediated hepatotoxicity of 
clinically used drugs and investigational drugs.  
A full pre-clinical PET imaging study using [18F]-4c is currently in progress and will be reported in due 
course. 
 
4. Experimental  
Bile acids, chemicals and solvents used in the synthesis, rifamycin SV, sodium fusidate, Dulbecco’s 
modified essential media (DMEM), Hanks’ balanced salt solution (HBSS) and triton X-100 were 
purchased from Sigma-Aldrich UK. UltimaGold and Monoscint 20 scintillation cocktails were 
obtained from PerkinElmer Life and Analytical Sciences UK. Phosphate-buffered saline (without CaCl2 
and MgCl2), geneticin (G418), and L-glutamine were purchased from Invitrogen, UK. Heat inactivated 
foetal calf serum was procured from PAA Laboratories GmbH UK. BD Biocoat™ Poly-D-lysine 24-
multiwell plates were purchased from BD Biosciences (Oxford, UK). Costar 96-well round bottom 
polypropylene microplates (Corning Inc.) were obtained from ThermoFisher Scientific. Multiscreen 
HTS 96-well GF/B filter plates and TopCount adaptors were purchased from Millipore (UK) Ltd. 
(Watford, UK). BD Falconä HTS 96-well flat bottom, tissue culture treated microplates were supplied 
by BD Biosciences Discovery Labware (Bedford, MA USA). Unifilter350 microplate GF-C plates were 
supplied by VWR. TopSeal A adhesive sealing film were obtained from PerkinElmer Life and 
Analytical Sciences (USA). Pierce® BCA Protein Assay kit was purchased from ThermoFisher Scientific 
UK. 
1H (400.13 MHz), 13C (100.58 MHz) and 19F (376.45 MHz) NMR spectra were recorded on a Bruker 
ADVANCE III spectrometer. 1H NMR chemical shifts are reported relative to the solvent resonance 
(CDCl3 δ = 7.26, CD3OD δ = 3.31 ). 13C NMR spectra were recorded with complete proton decoupling, 
and the chemical shifts are reported relative to the solvent resonance (CDCl3 δ = 77.0, CD3OD δ = 
49.0). The following abbreviations are used to describe spin multiplicity: s = singlet, d = doublet, dd = 
doublet-doublet, dt = doublet-triplet, t = triplet, dt = doublet-triplet, q = quartet, m = multiplet, bs = 
broad signal. All chemical shifts (δ) are expressed in parts per million and coupling constant (J) are 
given in Hertz. MS experiments were performed on an Agilent Technologies 1200 Series HPLC 
system equipped with a DAD and a 6120 MS detector composed by an ESI ionization source and a 
Single Quadrupole mass selective detector. HRMS were performed at the National Mass 
Spectrometry Facility (Swansea, UK). All reactions were carried out in oven- or flame-dried glassware 
under nitrogen atmosphere, unless stated otherwise. All commercially available reagents were used 
as received. Reactions were magnetically stirred. Flash chromatography was performed on silica gel 
(60 Å, particle size 0.040–0.062 mm). Yields refer to chromatographically and spectroscopically pure 
compounds, unless stated otherwise. The radiotracer synthesis and purification was performed 
using a Eckert and Ziegler ModularLab system equipped with the HPLC module. The purified hot 
tracer and the cold reference were analysed using a Shimadzu Prominence HPLC system equipped 
with a PDA UV detector and HERM LB500 activity detector. Phenomenex Luna C18 column, 5 μm, 
100 Å, 250 × 4.6 mm (L × ID) and Phenomenex Luna C18 column, 5 μm, 100 Å, 250 × 10.0 mm (L × ID) 
were used as analytical and semipreparative HPLC columns respectively.  
 
5.1 General procedure for the synthesis of compounds 2a-c 
To a mixture of bile acid (1.22 mmol) and HATU (465 mg, 1.33 mmol) in DMF (20 mL), DIPEA (1.2 mL. 
4.00 mmol) was added dropwise, followed by propargyclycine methyl ester hydrochloride (217 mg, 
1.33 mmol). The reaction mixture was stirred at room temperature for 3 h. Water (50 mL) was then 
added and HCl 2 M was used to adjust the pH= 2.5-3. The mixture was extracted with EtOAc (30 mL) 
and the organic phase was then washed with a saturated solution of NaHCO3 (30 mL) and brine 
(10mL). The organic phase was then dried over MgSO4 and the solvents removed at reduced 
pressure. The crude was purified via FCC using DCM/MeOH (15:1) as a mobile phase. 
5.1.1. Methyl 2-((R*)-4-((3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-trihydroxy-10,13-
dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanamido)pent-4-ynoate (2a) 
White amorphous solid in 87% yield (550 mg). 1H NMR (400 MHz, CDCl3) δ: 0.66 (s, 3H), 0.87 (s, 3H), 
0.92-1.12 (m, 5H), 1.26-1-92 (m, 18H), 2.04 (q, J = 2.6 Hz, 1H), 2.15-2.23 (m, 3H), 2.29-2.36 (m, 1H), 
2.74-2.75 (m, 2H), 3.05 (br s, 3H), 3.38-3.45 (m, 1H), 3.77 (s, 3H), 3.82, (br s, 1H), 3.95 (br s, 1H), 
4.71-4.76 (m, 1H), 6.54 (dd, J = 7.9, 2.8 Hz, 1H). 13C NMR (100 MHz, CDCl3) δ: 12.5, 17.4, 22.4, 23.3, 
26.3, 27.6, 28.1, 30.4, 31.4, 33.0, 33.1, 34.7, 34.8, 35.3, 39.5, 39.6, 41.5, 41.6, 46.4, 46.7, 46.8, 50.5, 
52.8, 68.5, 71.5, 71.6, 71.9, 73.1, 78.7, 171.1, 173.6. MS (ESI, m/z): C30H47NO6 [M+H]+ calc. 518.3 
found 518.3 
 
5.1.2. Methyl 2-((R*)-4-((3R,5R,8R,9S,10S,12S,13R,14S,17R)-3,12-dihydroxy-10,13-
dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanamido)pent-4-ynoate (2b) 
White amorphous solid, in 82% yield. 1H NMR (400 MHz, CDCl3) δ: 0. 64 (s, 3H), 0.87 (s, 3H), 0.95-
0.98 (m, 4H), 1.01-1.115 (m, 2H), 1.20-1.84 (m, 22H), 2.01-2.03 (m, 1H), 2.11-2.34 (m, 4H), 2.72-2.74 
(m, 2H), 3.53-3.60 (m, 1H), 3.75 (s, 1H), 3.95 (br. s, 1H), 4.70-4.74 (m, 1H), 6.41 (d, J = 7.9 Hz, 1H). 
NMR (100 MHz, CDCl3) δ: 12.7, 17.4, 22.4, 23.1, 23.7, 26.2, 27.2, 27.5, 28.6, 60.4, 31.4, 33.2, 33.3, 
33.6, 34.1, 35.2, 35.3, 36.0, 36.4, 42.1, 46.5, 47.1, 48.1, 50.5, 52.8, 71.6, 71.7, 73.1, 78.6, 171.0, 
171.1, 173.4. MS (ESI, m/z): C30H47NO5 [M+H]+ calc. 502.3 found 502.3 
 
5.1.3. Methyl 2-((R*)-4-((3R,5R,8R,9S,10S,13R,14S,17R)-3-hydroxy-10,13-dimethylhexadecahydro-1H-
cyclopenta[a]phenanthren-17-yl)pentanamido)pent-4-ynoate (2c) 
White amorphous solid, in 92% yield. 1H NMR (400 MHz, CDCl3) δ: 0.62 (s, 3H), 0.90-1.15 (m, 13H), 
1.22-1.57 (m, 12H), 1.63-1.66 (m, 1H), 1.70-1.85 (m, 6H) 1.93-1.96 (m, 1H), 2.01 (t, J = 2.5 Hz, 1H), 
2.10-2.18 (m, 1H), 2.27-2.34 (m, 1H), 2.74-2.76 (m, 1H), 3.56-3.64 (m, 1H), 3.77 (s, 3H), 4.71-4.76 (m, 
1H), 6.28 (d, J = 7.7 Hz, 1H).   13C NMR (100 MHz, CDCl3) δ: 12.1, 18.4, 20.8, 22.5, 23.4, 24.2, 26.4, 
27.2, 28.3, 30.5, 31.5, 33.3, 33.4, 34.6, 35.4, 35.9, 36.5, 40.2, 42.1, 42.8, 50.4, 52.8, 56.0, 56.5, 71.5, 
71.8, 78.5, 171.0, 173.3. MS (ESI, m/z): C30H47NO4 [M+H]+ calc. 486.4 found 486.4 
 
5.2 General procedure for the synthesis of compounds 3a-c 
1-Bromo-4-fluorobutane (155 mg, 1 mmol) was dissolved in DMF (0.5 mL) and NaN3 was added (98 
mg, 1.5 mmol). The mixture was stirred overnight. Et2O (1 mL) and H2O (1mL) were added and the 
organic layer was transferred to a suspension of alkyne 2 (0.5 mmol) in tBuOH/H2O (2:1, 3 mL). 
CuSO4 (8 mg, 0.05 mmol) and sodium ascorbate (30 mg, 0.15 mmol) were added and the reaction 
mixture was stirred for 48 hours at room temperature. Saturated NH4Cl (10 mL) was added, the 
mixture was extracted with EtOAc (3X 10 mL) and the organic phase was dried over MgSO4, solvents 
were removed under reduced pressure and the crude product was purified by FCC (DCM/MeOH 
gradient from 15:1 to 10:1).  
5.2.1 methyl 3-(1-(4-fluorobutyl)-1H-1,2,3-triazol-4-yl)-2-((R*)-4-
((3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-trihydroxy-10,13-dimethylhexadecahydro-1H-
cyclopenta[a]phenanthren-17-yl)pentanamido)propanoate (3a) 
Prepared from alkyne 2a, white foam, 89% yield. 1H NMR (400 MHz, CDCl3) δ: 0.67 (s, 3H), 0.88 (s, 
3H), 0.94-1.00 (m, 4H), 1.03-1.15 (m, 1H), 1.23-1.31 (m, 1H), 1.38-1.44 (m, 4H), 1.49-1.95 (m, 16H), 
2.00-2.08 (m, 2H), 2.13-2.31 (m, 6H), 3.18-3.25 (m, 2H), 3.42-3.47 (m, 1H), 3.71 (s, 1H), 3.84 (br s, 
1H), 3.96 (br s, 1H), 4.36-4.42 (m, 3H), 4.52 (t, J = 5.7 Hz, 1H), 4.87-4.93 (m, 1H), 6.80-6.85 (m, 1H), 
7.40 (s, 1H). 19F NMR (376.45 MHz, CDCl3) δ: -218.94, -218.91. 13C NMR (100 MHz, CDCl3) δ: 12.5, 
17.4, 22.5, 23.2, 26.5, 27.2 (d, J = 20.1 Hz), 27.5, 27.9, 28.2, 29.7, 30.5, 31.3, 33.0, 34.6, 34.7, 35.3, 
39.6, 39.7, 41.5, 41.9, 46.5, 46.6, 49.8, 51.6, 52.5, 54.6, 68.4, 71.9, 73.0, 83.3 (d, J = 165.5 Hz), 122.1, 
143.1, 171.8, 173.8. MS (ESI, m/z): C34H55FN4O6 [M+H]+ calc. 635.4 found 635.4 
 
5.2.2 Methyl 2-((R*)-4-((3R,5R,8R,9S,10S,12S,13R,14S,17R)-3,12-dihydroxy-10,13-
dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanamido)-3-(1-(4-fluorobutyl)-1H-
1,2,3-triazol-4-yl)propanoate (3b) 
Prepared from alkyne 2b, white foam, 85% yield. 1H NMR (400 MHz, CDCl3) δ: 0.67 (s, 3H), 0.88 (s, 
3H), 0.94-1.00 (m, 4H), 1.03-1.15 (m, 1H), 1.23-1.31 (m, 1H), 1.38-1.44 (m, 4H), 1.49-1.95 (m, 16H), 
2.00-2.08 (m, 2H), 2.13-2.31 (m, 6H), 3.18-3.25 (m, 2H), 3.42-3.47 (m, 1H), 3.71 (s, 1H), 3.84 (br s, 
1H), 3.96 (br s, 1H), 4.36-4.42 (m, 3H), 4.52 (t, J = 5.7 Hz, 1H), 4.87-4.93 (m, 1H), 6.80-6.85 (m, 1H), 
7.40 (s, 1H). 19F NMR (376.45 MHz, CDCl3) δ: -218.94, -218.91. 13C NMR (100 MHz, CDCl3) δ: 12.8, 
17.4, 23.2, 23.7, 26.1, 26.5, 27.1, 27.3, 27.4, 27.5, 27.8, 27.9, 29.7, 30.5, 31.4, 33.2, 33.6, 34.1, 35.2, 
35.3, 36.0, 36.5, 42.1, 46.5, 47.0, 47.1, 49.8, 51.6, 52.5, 71.7, 73.1, 82.4, 84.0, 122.0, 143.1, 171.7, 
171.8, 173.6 MS (ESI, m/z): C34H55FN4O5 [M+H]+ calc. 619.4 found 619.4 
 
5.2.3 Methyl 3-(1-(4-fluorobutyl)-1H-1,2,3-triazol-4-yl)-2-((R*)-4-((3R,5R,8R,9S,10S,13R,14S,17R)-3-
hydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-
yl)pentanamido)propanoate (3c) 
Prepared from alkyne 2c, white foam, 86% yield.  1H NMR (400 MHz, CDCl3) δ: 0.60 (s, 3H), 0.87-0.89 
(m, 6H), 0.94-1.40 (m, 18H), 1.46-1.54 (m, 2H), 1.62-2.12 (m, 13H), 2.20-2.29 (m, 1H), 3.15-3.26 (m, 
2H), 5.55-3.63 (m, 1H), 3.68 (s, 3H), 4.34-4.40 (m, 3H), 4.50 (t, J = 5.6 Hz, 1H), 4.85-4.90 (m, 1H), 6.64 
(d, J = 7.7 Hz, 1H), 7.34 (s, 1H). 19F NMR (376.45 MHz, CDCl3) δ: -219.00, -219.01. 13C NMR (100 MHz, 
CDCl3) δ: 12.0, 18.3, 20.8, 23.4, 24.2, 26.4, 26.5, 27.1, 27.2, 27.3, 27.8, 28.2, 30.5, 31.5, 33.4, 34.6, 
35.4, 35.8, 36.5, 40.1, 40.4, 42.1, 42.7, 49.7, 51.5, 52.5, 56.0, 56.4, 71.7, 82.4, 84.0, 122.0, 143.1, 
171.7, 173.6. MS (ESI, m/z): C34H55FN4O4 [M+H]+ calc. 603.4 found 603.4 
 
5.3 General procedure for the synthesis of compounds 4a-c 
The methyl ester 3 (100 mg, 0.157 mmol) was dissolved in MeOH (2 mL) and KOH 2 M (1 mL) was 
added. The mixture was stirred at room temperature for 3 hours, the volatile components were 
removed, H2O (2mL) was added and concentrated HCl was added dropwise to precipitate the acid 4.  
5.3.1. 3-(1-(4-fluorobutyl)-1H-1,2,3-triazol-4-yl)-2-((R*)-4-((3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-
3,7,12-trihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-
yl)pentanamido)propanoic acid (4a), CATD 
Prepared from methyl ester 3a, 96 mg, 98% yield as a white solid.1H NMR (400 MHz, CD3OD) δ: 0.71 
(s, 3H), 0.93 (s, 3H), 0.96-1.16 (m, 5H), 1.28-1.49 (m, 7H), 1.52-1.89 (m, 12H), 1.94-2.06 (m, 6H), 2.10-
2.019 (m, 1H), 2.23-2.34 (m, 3H), 3.09-3.15 (m, 1H), 3.28-3.29 (m, 1H), 3.35-3.42 (m, 1H), 3.80-3.82 
(m, 1H), 3.96 (br s, 1H), 4.39-4.45 (m, 3H), 4.52 (t, J = 5.8 Hz, 1H), 4.71-4.75 (m, 1H), 7.79 (s, 1H). 19F 
NMR (376.45 MHz, CD3OD) δ: -220.53, -220.52. 13C NMR (100 MHz, CD3OD) δ: 11.6, 16.3, 21.8, 22.8, 
26.1, 26.5, 27.0 (d, J = 20.1 Hz), 27.3, 27.4, 28.2, 29.8, 31.7, 32.4, 34.5, 35.1, 35.4, 39.1, 39.6, 41.6, 
41.8, 46.1, 46.7, 49.5, 52.0, 60.2, 67.7, 71.5, 72.7, 82.8 (d, J = 164.3 Hz), 122.9, 143.4 (br signal), 
172.7, 175.3. MS (ESI, m/z): C33H53FN4O6  [M+H]+ calc. 621.4 found 621.4 
5.3.2.  
 
((R*)-4-((3R,5R,8R,9S,10S,12S,13R,14S,17R)-3,12-dihydroxy-10,13-dimethylhexadecahydro-1H-
cyclopenta[a]phenanthren-17-yl)pentanamido)-3-(1-(4-fluorobutyl)-1H-1,2,3-triazol-4-yl)propanoic 
acid (4b) 
Prepared from the ester 3b, white solid, 98% yield. 1H NMR (400 MHz, CDCl3) δ: 0.66 (s, 3H), 0.90 (s, 
3H), 0.94 (dd, J= 15.3, 6.0 Hz, 2H), 1.02-1.12 (m, 2H), 1.20-1.85 (m, 25H), 2.00-2.07 (m, 2H), 2.11-2.19 
(M, 1H), 2.23-2.29 (M, 1H), 3.29 (d, J= 6.0 Hz, 2H), 3.57-3.64 (m, 1H), 3.99 (d, J= 2.4 Hz, 1H), 4.37-
4.41 (m, 3H), 4.52 (t, J= 5.7 Hz, 1H), 4.79-4.81 (m, 1H), 7.23 (d, J= 8. Hz, 1H), 5.54 (s, 1H). 19F NMR 
(376.45 MHz, CDCl3) δ: -218.69, -218.72. 13C NMR (100 MHz, CDCl3) δ: 12.7, 17.3, 17.4, 23.1, 23.7, 
26.2, 26.4, 26.5, 27.1, 27.3, 27.6, 28.4, 29.7, 30.2, 31.4, 33.5, 34.2, 35.3, 36.0, 36.1, 42.1, 46.5, 46.6, 
48.1, 50.0, 52.1, 71.7, 73.4, 82.4, 84.1, 122.8, 143.3, 143.5, 173.2, 174.8, 174.9. MS (ESI, m/z): 
C33H53FN4O5  [M+H]+ calc. 605.4 found 605.4 
 
5.3.3 3-(1-(4-fluorobutyl)-1H-1,2,3-triazol-4-yl)-2-((R*)-4-((3R,5R,8R,9S,10S,13R,14S,17R)-3-hydroxy-
10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanamido)propanoic acid 
(4c), LCATD 
Prepared from the ester 3c, white solid, 98% yield.1H NMR (400 MHz, CDCl3) δ: 0.62 (s, 3H), 0.87-2.14 
(m, 37H), 2.25-2.31 (m, 1H), 3.32-3.37 (m, 2H), 3.60-3.65 (m, 2H), 4.38-4.42 (m, 3H), 4.50-4.53 (m, 
1H), 4.72-4.73 (m, 1H), 6.87 (br. s, 1H) 7.48 (s, 1H). 19F NMR (376.45 MHz, CDCl3) δ: -219.27. 13C NMR 
(100 MHz, CD3OD) δ: 11.2, 17.5, 20.1, 22.6, 23.9, 26.1, 26.2, 26.3, 27.0, 27.2, 27.5, 27.9, 29.8, 31.7, 
32.5, 34.3, 35.1, 35.4, 35.8, 35.9, 40.1, 40.5, 42.2, 42.5, 49.5, 56.0, 56.5, 71.0, 82.0, 83.7, 122.9, 
143.5, 175.1 HRMS (ESI, m/z): C33H53FN4O4  [M+H]+ calc. 589.4051 found 589.4062    
 
5.4 General procedure for the synthesis of compounds 5a-c 
Alkyne 2 (0.5 mmol) was dissolved in THF (2.5 mL) and treated with N-iodomorpholine-hydrogen 
iodide (260 mg, 0.75 mmol) followed by CuI (10 mg, 0.05 mmol). Sample was stirred for 2 hours and 
after this time the suspension was poured onto a pad of neutral alumina (~10 mL) and the solution 
was collected under vacuum. The pad was then washed 3 times with a solution of methanol in DCM 
(5%, 10 mL). The volatile were evaporated to give a yellow wax. 1-fluoro-4-azidobutane 
(approximately 0.75 mmol, unpurified) THF (2.5 mL), CuI and (5 mg, 0.025 mmol) TEA (140 μL, 1.00 
mmol) were added. The mixture was stirred at room temperature for 24 hours. After this time the 
reaction was quenched by adding 1 mL of 10% NH4OH solution. The crude mixture was extracted 
with ethyl acetate (3 X 10 mL), washed with brine, dried over MgSO4 and the volatile components 
were removed by evaporation. The crude was purified by FCC (DCM/MeOH gradient from 15:1 to 
10:1)).  
5.4.1 Methyl 3-(1-(4-fluorobutyl)-5-iodo-1H-1,2,3-triazol-4-yl)-2-((R*)-4-
((3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-trihydroxy-10,13-dimethylhexadecahydro-1H-
cyclopenta[a]phenanthren-17-yl)pentanamido)propanoate (5a) 
Prepared from alkyne 2a, 300 mg, 80% yield, pale yellow foam.  1H NMR (400 MHz, CDCl3) δ: 0.66 (s, 
3H), 0.87 (s, 3H), 0.95-0.97 (m, 4H), 1.05-1.14 (m, 1H), 1.23-1.27 (m, 1H), 1.38-1.44 (m, 4H), 1.47-
1.59 (m, 4H), 1.65-1.79 (m, 8H), 1.85-1.95 (m, 3H), 2.00-2.08 (m, 2H), 2.12-2.32 (m, 6H), 3.12-3.23 
(m, 2H), 3.39-3.47 (m, 1H), 3.72 (s, 3H), 3.83 (br s, 1H), 3.95 (br, 1H), 3.38-3.43 (m, 3H), 4.53 (t, J= 5.7 
Hz, 1H), 4.90-4.95 (m, 1H), 6.76-6.81 (m, 1H). 19F NMR (376.45 MHz, CDCl3) δ :  -219.12, -219.14. 13C 
NMR (100 MHz, CDCl3) δ:  12.5, 17.4, 22.5, 23.2, 25.9, 26.0, 26.5, 27.2 (d, J = 20.0 Hz), 27.5, 28.1, 
28.2, 30.5, 31.3, 33.1, 33.2, 34.6, 34.7, 35.3, 39.6, 39.7, 41.5, 41.8, 46.5, 46.7, 46.8, 50.4, 51.1, 52.6, 
68.4, 71.9, 73.0, 77.2, 79.8, 83.1 (d, J = 165.8 Hz), 147.5, 171.5, 173.6, 173.7. MS (ESI, m/z): 
C34H55IFN4O6 calc.761.3, found 761.3 
 
5.4.2. Methyl 2-((R*)-4-((3R,5R,8R,9S,10S,12S,13R,14S,17R)-3,12-dihydroxy-10,13-
dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanamido)-3-(1-(4-fluorobutyl)-5-
iodo-1H-1,2,3-triazol-4-yl)propanoate (5b) 
Prepared from alkyne 2b, 297 mg, 80% yield, pale yellow foam. 1H NMR (400 MHz, CDCl3) δ: 0.66 (s, 
3H), 0.90 (s, 3H), 0.94-1.87 (m, XH), 2.02-2.09 (m, 2H), 2.12-2.18 (m, 1H), 2.25-2.32 (m, 1H), 3.12-
3.24 (m, 2H), 3.56-3.64 (m, 1H), 3.73 (s, 3H), 3.97 (br. s, 1H), 4.39-4.43 (m, 3H), 4.53 (t, J= 5.8 Hz, 1H), 
4.92-4.96 (m, 1H), 6.66 (d, J= 8.0 Hz, 1H). 19F NMR (376.45 MHz, CDCl3) δ :  -219.21. 13C NMR (100 
MHz, CDCl3) δ: 12.8, 17.5, 23.2, 23.7, 25.9, 26.1, 27.1, 27.3, 27.4, 27.5, 28.1, 28.6, 30.5, 31.3, 33.3, 
33.7, 34.1, 35.1, 35.2, 36.0, 36.5, 42.1, 46.5, 47.2, 48.2, 50.4, 51.0, 52.6, 71.8, 73.1, 77.2, 79.6, 82.3, 
83.9, 147.5, 171.4, 171.5, 173.4. MS (ESI, m/z): C34H55FIN4O5 [M+H]+ calc. 745.3 found 745.3. 
 
5.4.3. Methyl 3-(1-(4-fluorobutyl)-5-iodo-1H-1,2,3-triazol-4-yl)-2-((R*)-4-
((3R,5R,8R,9S,10S,13R,14S,17R)-3-hydroxy-10,13-dimethylhexadecahydro-1H-
cyclopenta[a]phenanthren-17-yl)pentanamido)propanoate (5c) 
Prepared from alkyne 2c, 290 mg, 80% yield, pale yellow foam.1H NMR (400 MHz, CDCl3) δ: 0.66 (s, 
3H), 0.88-0.90 (m, 6H), 0.95-1.41 (m, 18H), 1.48-1.58 (m, 4H), 1.64-1.86 (m, 8H), 1.92-1.95 (m, 1H), 
2.01-2.15 (m, 3H), 2.24-2.31 (m, 1H), 3.12-3.24 (m, 2H), 3.56-3.65 (m ,1H), 3.72 (s, 3H), 4.39-4.43 (m, 
3H), 4.53 (t, J= 5.7 Hz, 1H), 4.91-4.97 (m, 1H), 6.61 (d, J= 7.8 Hz, 1H). 19F NMR (376.45 MHz, CDCl3) δ :  
-219.27. 13C NMR (100 MHz, CDCl3) δ: 12.1, 18.3, 20.8, 23.4, 24.2, 25.9, 26.4, 27.1, 27.2, 27.3, 28.1, 
28.2, 30.6, 31.4, 33.4, 34.6, 35.4, 35.4, 35.5, 35.9, 36.5, 40.2, 40.4, 42.1, 42.7, 50.4, 50.0, 52.6, 56.0, 
56.5, 71.9, 77.2, 79.6, 82.3, 83.9, 147.5, 162.5, 171.5, 173.4. MS (ESI, m/z): C34H55FIN4O4 [M+H]+ calc. 
729.3 found 729.3. 
 
5.5. Tritium labelling 
Labelling with tritium was performed according to the previously reported procedure.21 
 
5.6. Synthesis of precursors for radiofluorination  
5.6.1 Methyl 2-((R*)-4-((3R,5R,8R,9S,10S,13R,14S,17R)-3-acetoxy-10,13-dimethylhexadecahydro-1H-
cyclopenta[a]phenanthren-17-yl)pentanamido)pent-4-ynoate (6) 
To a solution of alkyne 2c (200 mg, 0.41 mmol) in anhydrous pyridine (1 mL), acetic anhydride (78 µL, 
0.82 mmol) was added. The mixture was stirred for 3 hours at room temperature. The solvent was 
removed under reduced pressure and the crude was dissolved in AcOEt and washed with a saturated 
solution of NaHCO3. The organic phase was dried over MgSO4, the solvent was removed and the 
product purified via FCC (Hex/AcOEt 8:2) to give the title compound as a white foam in quantitative 
yield (215 mg).   
1H NMR (400 MHz, CDCl3) δ: 0.64 (s, 3H), 0.92-0.94 (m, 6H), 1.02-1.45 (m, 17H),1.52-1.57 (m, 2H), 
1.67-1.69 (m, 1H), 1.78-1.88 (m, 5H), 1.95 (d, J = 11.7 Hz, 1H), 2.0.2-2.04 (m, 4H), 2.12-2.20 (m, 1H), 
2.28-2.35 (m, 1H), 2.76-2.78 (m, 2H), 3.79 (s, 3H), 4.67-4.78 (m, 1H), 6.24 (d, J = 7.8 Hz, 1H).  13C NMR 
(100 MHz, CDCl3) δ: 12.0, 18.3, 20.8, 21.3, 22.3, 23.3, 24.1, 26.3, 26.5, 26.9, 28.1, 31.4, 31.5, 32.2, 
33.1, 34.5, 35.0, 35.3, 35.7, 40.1, 40.3, 41.8, 42.7, 50.5, 52.6, 56.0, 56.4, 71.4, 74.2, 77.4, 78.6, 170.4, 
170.9, 173.1. MS (ESI, m/z): C32H50NO5 [M+H]+ calc. 528.3 found 528.3 
 
5.6.2. Methyl 2-((R*)-4-((3R,5R,8R,9S,10S,13R,14S,17R)-3-acetoxy-10,13-dimethylhexadecahydro-1H-
cyclopenta[a]phenanthren-17-yl)pentanamido)-3-(1-(4-hydroxybutyl)-1H-1,2,3-triazol-4-
yl)propanoate (7) 
Prepared from alkyne 6 and 4-azido-1-butanol according to the general procedure for triazole 
synthesis in 90% yield. 1H NMR (400 MHz, CDCl3) δ: 0.62 (s, 3H), 0.89-0.91 (m, 6H), 1.00-1.13 (m, 5H), 
1.12-1.14 (m, 1H), 1.21-1.26 (m, 3H), 1.29-1.45 (m, 8H), 1.49-1.57 (m, 4H), 1.65-1.87 (m, 7H), 1.93-
1.96 (m, 1H), 2.02 (s, 3H), 2.06-2.13 (m, 1H), 2.21-2.30 (m, 1H), 3.21 (d, J = 5.4 Hz, 2H), 3.48 (s, 
1H),3.63 (t, J = 6.1 Hz, 2H), 3.71 (s, 3H), 4.37 (t, J = 7.0 Hz, 2H), 4.67-4.75 (m, 1H), 4.90-4.93 (m, 1H), 
6.58 (d, J = 8.0 Hz, 1H), 7.38 (s, 1H). 13C NMR (100 MHz, CDCl3) δ: 12.0, 18.2, 20.7, 21.4, 23.3, 24.1, 
26.2, 26.5, 26.8, 26.9, 27.8, 28.1, 29.1, 31.4, 32.1,  33.2, 34.4, 34.9, 35.3, 35.4, 35.7, 40.1, 40.3, 41.8, 
42.6, 50.0, 50.1, 51.6, 52.4, 56.0, 56.4, 61.3, 74.3, 122.1, 142.8, 170.7, 171.7, 173. 8. MS (ESI, m/z): 
C36H59N4O6 [M+H]+ calc. 643.4 found 643.4. 
 
5.6.3. Methyl 2-((R*)-4-((3R,5R,8R,9S,10S,13R,14S,17R)-3-acetoxy-10,13-dimethylhexadecahydro-1H-
cyclopenta[a]phenanthren-17-yl)pentanamido)-3-(1-(4-(methylsulfonyloxy)butyl)-1H-1,2,3-triazol-4-
yl)propanoate (8) 
Compound 7 (100 mg, 0.16 mmol) was dissolved in anhydrous DCM (1 mL) at 0 °C. TEA (32 µL, 0.23 
mmol) was added followed by mesylchloride (18 µL, 0.23 mmol). The reaction was stirred at 0 °C for 
4 hours (complete conversion by TLC analysis). A saturated NaHCO3 solution (1 mL) was added, the 
mixture was extracted with DCM (2 x 3 mL) and the organic phase was dried over MgSO4. The title 
compound was obtained after FCC (Hex/AcOET 8:2) to give the title compound as a white foam in 
quantitative yield.   
1H NMR (400 MHz, CDCl3) δ: 0.63 (s, 3H), 0.90-0.92 (m, 6H), 10.1-1.46 (m, 19H), 1.51-1.56 (m, 2H), 
1.61 (s, 1H), 1.66-1.84 (m, 8H), 1.94-1.80 (m, 1H), 2.02-2.21 (m, 6H), 2.22-2.32 (m, 1H), 3.01 (s, 3H), 
3.18-3.28 (m, 2H), 3.71 (s, 3H), 4.23 ((t, J = 6.1 Hz, 2H), 4.38 (t, J = 6.9 Hz, 2H), 4.67-4.75 (m, 1H), 
4.90-4.94 (m, 1H), 6.56 (d, , J = 8.4 Hz, 1H), 7.35 (s, 1H). 13C NMR (100 MHz, CDCl3) δ: 12.0, 18.3, 20.8, 
21.5, 23.3, 24.1, 26.1, 26.3, 26.6, 27.0, 27.8, 31.5, 32.2, 33.3, 34.6, 35.0, 35.4, 35.5, 35.8, 40.1, 40.3, 
41.9, 42.7, 49.4, 51.5, 52.5, 56.0, 56.4, 68.8, 74.4, 122.1, 143.2, 170.7, 171.7, 173.6. MS (ESI, m/z): 
C37H61N4O8S [M+H]+ calc. 721.4 found 721.4. 
 
5.7. Cell culture and BSEP membrane vesicles 
HEK293-OATP1B1, HEK293-OATP1B3 and HEK293-MOCK transfected cells were grown by the 
AstraZeneca’s cell culture facility in Alderley Park, UK on 225 cm2 Costar® cell culture flasks at 37°C in 
a humidified 5% CO2 atmosphere using DMEM medium supplemented with 10% (v/v) foetal calf 
serum, 1 mg/mL of geneticin, and 4 mM of L-glutamine. The cells were plated 48 hours before assaying 
in BD Biocoat™ Poly-D-lysine 24-well plates at a density 0.25 million cells per well. 
A recombinant cell line expressing NTCP, CHO-NTCP and parental CHO cell lines were obtained from 
Cell Bank of AstraZeneca, Alderley Park, UK. The CHO-NTCP and CHO parental cells were grown on 75 
cm2 or 225 cm2 Costar® cell culture flasks at 37 oC in a humidified 5% CO2 atmosphere using Dulbecco’s 
Modified Essential Medium (DMEM) medium supplemented with 10  % (v/v) foetal calf serum, 4 mM 
of L-glutamine.  CHO-NTCP cell cultures additionally included 1 mg/mL of geneticin during the growth 
of cultures. The cells were maintained sub-confluent and split twice weekly, 1:3 - 1:10 depending on 
their density. The cells were cultured in BD Biocoat™ Poly-D-lysine 24-well multiwell plates for 
assaying and were plated 72 hours prior to assaying at a cell density of 0.25 million cells per well. 
Human BSEP membrane vesicles (derived from plasma membrane of transfected Spodoptera 
frugiperda (Sf) 21 cells expressing most common variant of human BSEP) were prepared at Reagents 
& Assay Development group in Discovery Sciences, AstraZeneca R&D (Alderley Park, UK). 
 
5.8.  Transport study  
Cellular uptake of tritium labeled compounds was measured using monolayer cultures of 
HEK293-OATP1B1, HEK293-OATP1B3, HEK293-MOCK, CHO-NTCP and CHO parental cells grown on 24-
well plates as described previously,6,22 with specific adaptation as described in the following sections.  
The tritiated test compound was diluted in HBS (pH adjusted to 7.4) to obtain 30 mL of 0.05 µM 
working solution (about 37 KBq mL-1) which was warmed to 37 °C prior to assays. Concentration 
dependent uptake of the potential PET tracer was studied over a range of six concentrations having 
activity of about 37 KBq mL-1. The culture media was removed from the 24-well plates containing the 
desired cell line at about 100% confluence. Cells were washed three times (3 × 0.5 mL) with pre-
warmed (37 °C) HBS solution (pH adjusted to 7.4). The medium was carefully removed by aspiration 
using a vacuum pump. The third wash of HBS solution was left on the cells and the plate was warmed 
on a bench top incubator at 37 °C for 15 minutes before starting the uptake assays. The HBS solution 
was removed from the wells immediately prior to start of the assay.  
To start the uptake assay, 0.5 mL of pre-warmed test compound solution were added to the wells 
(experiments were performed in triplicate) by using a multipipette and the plate was returned to the 
bench incubator at 37 °C. At the designed time, the solution containing the test compound was 
carefully removed from the wells by aspiration and the cells were washed three times (3 × 1 mL) with 
ice-cold HBS solution (pH 7.4). Cells were lysed by adding Triton X-100 (0.5 mL, 0.1% v/v) to each well. 
The plates were gently shaken for 30 min at room temperature and the lysate (200 μl) was transferred 
into 10 mL glass scintillation vials containing Ultima Gold® scintillation cocktail (5 mL) for liquid 
scintillation counting. The plates containing the cell lysate were stored at –20 °C for protein analysis. 
The amount of protein content per well was determined as a mean of six wells per plate using the 
Pierce® BCA Protein assay kit.  
Transport of tritiated test compounds in HEK293-OATP1B1 and HEK293-MOCK transfected cells was 
assessed in the presence and absence of the inhibitor rifamycin SV in a range of 6-concentrations with 
the aim to determine IC50 values for the inhibition of OATP1B1-mediated transport.  
Rifamycin SV was dissolved in DMSO to obtain a primary 10 mM stock solution which was diluted with 
pre-warmed HBS solution (pH 7.4) to obtain six pre-incubation solutions of rifamycin SV at 100, 10, 1, 
0.1, 0.01, 0.001 μM. Content of DMSO was kept constant at 1 % (v/v). To obtain the six co-incubation 
solutions, the secondary stock solutions of rifamycin SV were diluted 100 times with HBS (pH adjusted 
to 7.4) containing 0.05 µM (37 KBq mL-1) of the tritiated substrate.  
The culture media was removed from the 24-well plates containing HEK293-OATP1B1 cells at about 
100% confluence. Cells were washed three times (3 × 0.5 mL) with pre-warmed (37 °C) HBS solution 
(pH 7.4) and replaced by the pre-incubation solutions containing the inhibitor. The plate was 
incubated at 37 °C for 15 minutes. After this time, the pre-incubation solutions were removed and the 
uptake was initiated by adding to the working solution containing the inhibitor at 0.001, 0.01, 0.1, 1, 
10, 100 μM and the labeled substrate. The plate was returned to the incubator and after 8 minutes of 
incubation the working solutions were removed from the wells and the cells treated as previously 
described. 
The concentration of substrate into the cell lysate, Clysate (pmol ml−1) was calculated from the DPM 
(disintegration per minute) values obtained by liquid scintillation counting of the samples from the 
specific activity SA (in KBq pmol-1) of the test solution using the equation (1)  
 
𝐶𝐶𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙 = 𝐷𝐷𝐷𝐷𝐷𝐷𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠60000𝑆𝑆𝑆𝑆      (equation 1) 
 
where 60000 is the conversion factor between disintegration per minute (DPM) and KBq.   
The uptake rate U was calculated with the equation (2), where U is the rate of uptake of substrate in 
the cells (pmol min−1 mg−1); T is the time of incubation (min); P is the mean protein content (mg ml−1) 
per well; and Clysate is the substrate concentration in cell lysate (pmol ml−1):  
 
𝑈𝑈 = 𝐶𝐶𝑠𝑠𝑙𝑙𝑠𝑠𝑠𝑠𝑙𝑙𝑠𝑠
𝑇𝑇 ∙𝑃𝑃     (equation 2) 
 
The net TRANSPORTER-mediated substrate transport UTRANSPORTER (pmol min−1 mg−1) was determined 
as the difference between the uptake rate in TRANSPORTER-expressing cells (UTRANSPORTER-expressing cell) 
and MOCK-cells (UMOCK cell) (equation 3):  
 
𝑈𝑈𝑇𝑇𝑇𝑇𝑆𝑆𝑇𝑇𝑆𝑆𝑃𝑃𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇  = 𝑈𝑈𝑇𝑇𝑇𝑇𝑆𝑆𝑇𝑇𝑆𝑆𝑃𝑃𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 𝑙𝑙𝑒𝑒𝑒𝑒𝑒𝑒𝑙𝑙𝑙𝑙𝑙𝑙𝑒𝑒𝑒𝑒𝑒𝑒 𝑐𝑐𝑙𝑙𝑙𝑙𝑙𝑙 −  𝑈𝑈𝑀𝑀𝑇𝑇𝐶𝐶𝑀𝑀 𝑐𝑐𝑙𝑙𝑙𝑙𝑙𝑙       (equation 3) 
 
The influx or uptake ratio, defined as the ratio of the uptake rate in TRANSPORTER-expressing cells 
(UTRANSPORTER-expressing cell) and MOCK-cells (UMOCK cell), was calculated according to equation 4and its 
uncertainty (𝛿𝛿𝑈𝑈𝛿𝛿𝛿𝛿𝛿𝛿𝛿𝛿𝛿𝛿 𝑅𝑅𝛿𝛿𝛿𝛿𝑅𝑅𝑅𝑅) according to equation 5:  
 
𝑈𝑈𝛿𝛿𝛿𝛿𝛿𝛿𝛿𝛿𝛿𝛿 𝑅𝑅𝛿𝛿𝛿𝛿𝑅𝑅𝑅𝑅 =  𝑈𝑈𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝐷𝐷𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 𝑠𝑠𝑒𝑒𝑠𝑠𝑒𝑒𝑠𝑠𝑠𝑠𝑠𝑠𝑒𝑒𝑒𝑒𝑒𝑒 𝑐𝑐𝑠𝑠𝑠𝑠𝑠𝑠
𝑈𝑈𝐷𝐷𝑇𝑇𝑀𝑀𝑀𝑀 𝑐𝑐𝑠𝑠𝑠𝑠𝑠𝑠            (equation 4) 
 
𝛿𝛿𝑈𝑈𝛿𝛿𝛿𝛿𝛿𝛿𝛿𝛿𝛿𝛿 𝑅𝑅𝛿𝛿𝛿𝛿𝑅𝑅𝑅𝑅 = 𝑈𝑈𝛿𝛿𝛿𝛿𝛿𝛿𝛿𝛿𝛿𝛿 𝑅𝑅𝛿𝛿𝛿𝛿𝑅𝑅𝑅𝑅 ∙ ��𝑆𝑆𝑆𝑆 𝑈𝑈𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝐷𝐷𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 𝑠𝑠𝑒𝑒𝑠𝑠𝑒𝑒𝑠𝑠𝑠𝑠𝑠𝑠𝑒𝑒𝑒𝑒𝑒𝑒 𝑐𝑐𝑠𝑠𝑠𝑠𝑠𝑠
𝑈𝑈𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝐷𝐷𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 𝑠𝑠𝑒𝑒𝑠𝑠𝑒𝑒𝑠𝑠𝑠𝑠𝑠𝑠𝑒𝑒𝑒𝑒𝑒𝑒 𝑐𝑐𝑠𝑠𝑠𝑠𝑠𝑠 �
2 + �𝑆𝑆𝑆𝑆 𝑈𝑈𝐷𝐷𝑇𝑇𝑀𝑀𝑀𝑀 𝑐𝑐𝑠𝑠𝑠𝑠𝑠𝑠
𝑈𝑈𝐷𝐷𝑇𝑇𝑀𝑀𝑀𝑀 𝑐𝑐𝑠𝑠𝑠𝑠𝑠𝑠 �2  (equation 5) 
 
Where SD represents  the standard deviation (n = 3). To determine if data sets obtained for the two 
cell lines were significantly different, Student’s t-test (Microsoft® Excel 2013) was applied. 
 GraphPad Prism (Version 6) (Michalis-Menten equation) was used to determine apparent Km 
and Vmax by plotting UTRANSPORTER (pmol min−1 mg−1) against substrate concentration.  
 To calculate the concentration of inhibitor that produces half-maximal inhibition (IC50) of 
transporter activity, UOATP1B1 was plotted as a percentage of control probe substrate (100% OATP1B1 
activity was assumed when no inhibitor was present) against inhibitor concentration. Transporter 
activity (% of control) is then calculated according to the following formula: % 𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂1𝐵𝐵1 ACTIVITY =  𝑧𝑧
𝑙𝑙
 ∙ 100            (equation6) 
where z is the OATP1B1 uptake of the probe in the presence of the inhibitor, y is the OATP1B1 uptake 
of the probe in the absence of the inhibitor.  
An IC50 value was obtained using a four-parameter logistic model (XLFit 5, Model 201) or any other 
appropriate model if needed: 
( )( ))101(
)(
*dxLogc
abay
−+
−
+=                (equation 7) 
where y is the % control activity and x is the logarithm of concentration of inhibitor, a and b are the 
vehicle and positive control and are locked to 0 and 100, respectively; c is the IC50 and d is the Hill 
slope of the curve.  
In order to understand the contribution of passive diffusion and the contribution of specific 
transporter OATP1B1 in the uptake of the PET probe compounds in HEK293-OATP1B1 cells, the 
OATP1B1-intrinsec clearance (or intrinsic capacity) Clint, OATP1B1 and passive diffusion clearance Pdiff were 
calculated by (equations 8-7)  
 
𝐶𝐶𝐶𝐶𝑒𝑒𝑒𝑒𝑙𝑙,𝑇𝑇𝑆𝑆𝑇𝑇𝑃𝑃1𝐵𝐵1 =  𝑉𝑉𝑠𝑠𝑠𝑠𝑒𝑒𝑀𝑀𝑠𝑠     (equation 8) 
 
𝐶𝐶𝐶𝐶𝑑𝑑𝑒𝑒𝑑𝑑𝑑𝑑 =  𝑈𝑈𝐷𝐷𝑇𝑇𝑀𝑀𝑀𝑀𝐶𝐶        (equation 9) 
 
where Vmax is the maximum rate of uptake, Km is the Michaelis-Menten constant, UMOCK is the uptake 
measured in HEK293-MOCK cells and C is the concentration of the substrate.  
 
Transport in BSEP-expressing membrane vesicles in the presence and absence of ATP was determined 
as described previously.12,23 Uptake solutions contained 1 % (v/v) DMSO containing the radiolabeled 
compound and the appropriate concentration of the corresponding non-radiolabeled compound and 
membrane vesicles in uptake buffer (HEPES/Tris pH 7.4: 25mM; KNO3 : 250mM; Sucrose: 125mM; 
Mg(NO3)2 :31mM). The 2 μl of test compound was added to the 96-well PCR assay plate followed by 
50 μl of 2-fold concentrated uptake buffer with ATP or AMP. The assay plate is kept on the heating 
block (37°C) and incubated for 3 min. Reaction was initiated by addition of 48 μl vesicle suspension 
per well. After 5 min incubation time 80 μl of the reaction mixture was transferred to the filter-plate 
containing 150 μl stop buffer (Sucrose: 50mM; KCl: mM, 100mM; HEPES/Tris pH 7.4: 10mM; 
Taurocholate: 0.1 mM; EDTA pH 7.4: 5mM). Filter-plate was transferred to the vacuum manifold and 
vacuum applied to trap the vesicles in the filter. Washed vesicles 4 times with 150 μl stop buffer, 
aspirating between each washing step. Filterplate was dried over night at room temperature. 150 μl 
of OptimaGold F was added per well and incubated for 10 min and plate sealed with TopSeal adhesive 
film. Radioactivity was measured on the Microbeta2 (Perkin Elmer, UK). 
The mean counts per minute (CPM) from three replicate wells containing an aliquot of the original 
uptake solution (containing buffer and vesicles) was determined and used to calculate the CPM/pmol 
normalisation factor: 
𝐶𝐶𝑃𝑃𝑀𝑀
𝑒𝑒𝑝𝑝𝑝𝑝𝑙𝑙
= 𝑇𝑇𝑝𝑝𝑙𝑙𝑙𝑙𝑙𝑙 𝐶𝐶𝑀𝑀𝑃𝑃(𝑇𝑇𝑝𝑝𝑙𝑙𝑙𝑙𝑙𝑙 𝜇𝜇𝑙𝑙 𝑙𝑙𝑙𝑙𝑒𝑒𝑎𝑎𝑎𝑎𝑝𝑝𝑙𝑙 )∙ (𝑇𝑇𝑝𝑝𝑙𝑙𝑙𝑙𝑙𝑙 µ𝑀𝑀 𝑝𝑝𝑑𝑑 𝑒𝑒𝑙𝑙𝑑𝑑𝑒𝑒𝑝𝑝𝑙𝑙𝑙𝑙𝑟𝑟𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑑𝑑 𝑐𝑐𝑝𝑝𝑝𝑝𝑒𝑒𝑝𝑝𝑎𝑎𝑒𝑒𝑑𝑑)   (equation 10) 
 
Where: Total CPM was the mean value of wells containing original uptake solution 
Total µl of aliquot was the volume of original uptake solution 
Total µM of radiolabeled compound was the concentration in the uptake solution prior 
to initiation of the incubation 
The CPM of each test sample well was determined and divided by the CPM/pmol normalisation factor 
to calculate the amount (pmol) of compound taken up by the vesicles. This amount was divided by the 
incubation time (min) and the protein amount in the incubation (mg) to give the uptake activity 
(pmol/min/mg). Mean (n = 3 wells) net BSEP transport activity was determined by subtracting 
transport in BSEP-transporter vesicles in the presence of ATP to that of transport in the presence of 
AMP. All experiments above were performed in triplicates at single occasion. 
 
5.9 Radiosynthesis of [18F]-LCATD 
Radiosynthesis, purification and formulation steps were performed in an Eckert & Ziegler ModularLab 
system equipped with semipreparative HPLC. [18F]Fluoride (~16 GBq) was delivered from the cyclotron 
into a stock vial and then separated from the [18O]H2O by means of a Chromafix PS-HCO3-ion exchange 
cartridge (Waters). [18F]Fluoride was then eluted with the solution of K2HPO4 (5 mg in 0.5 mL of sterile 
water) and collected in the reactor, followed by the solution of Kryptofix K222 (15 mg in 1 mL of 
anhydrous CH3CN). A first drying cycle was accomplished by heating at 95 °C under both vacuum and 
helium flow (400 seconds) and then under vacuum only (150 seconds) before delivering an additional 
amount of anhydrous CH3CN. The drying process was repeated and the solution of mesylate precursor 
8 (5 mg in 1 mL of anhydrous CH3CN) was then delivered into the reactor containing the [18F]KF-K222 
dry complex. The mixture was heated at 90 °C for 15 minutes. The reactor was cooled to 40 °C before 
adding the sodium hydroxide solution (0.5 mL, 2M in 50% aqueous methanol) which was allowed to 
react for 10 minutes. After the hydrolysis step, the crude reaction mixture was neutralized with 2M 
HCl (0.5 mL) and pumped into a vial containing the HPLC eluent (PBS/CH3CN 60:40, 1.5 mL). The 
mixture (about 3 mL) was then loaded in the 5 mL RP-HPLC loop and then injected in the Phenomenex 
Luna C18 column (5 µm, 250x10 mm, 100 Å), which was eluted with PBS/CH3CN 60:40 (5 mL min-1 
flow). The peak corresponding to the desired product was collected in a vial containing 50 mL of 
distilled water. The diluted solution of pure [18F]-LCATD ([18F]-4c) was then flushed through a C18 SPE 
cartridge Oasis® HLB Plus (Waters) in order to trap the tracer. The cartridge was then eluted with 
absolute ethanol (0.8 mL) and the resulting [18F]-LCATD was passed through a sterile filter and finally 
delivered into a vial, placed in a second hot cell, containing 7.2 mL of sterile PBS.  Up to 2 GBq of 
injectable solution of [18F]-LCATD were obtained (8 mL, up to 250 MBq mL-1). The total synthesis, 
purification and formulation time was about 90 minutes. The tracer was obtained in 25 ± 5 % (n = 5) 
decay corrected radiochemical yield. HPLC analysis of the formulated product confirmed the identity 
(co-injection with cold reference material) and the purity of the tracer (RCP >99%). Attempts to 
measure the specific activity of [18F]-LCATD failed due to the low UV absorbance of the tracer. 
 
5.10 PET/CT imaging experiment- pilot study  
The animal experiment was performed according to the University’s Code of Practice on the Use of 
Animals in Research as well as the legal requirements of the Animals Act 1986 and Home Office Code 
of Practice guidance. PET scans were performed with a small-animal PET/CT scanner (ARGUS-Sedecal, 
Spain) housed in a temperature-controlled suite. The scanner has two 11.8 cm diameter rings of 
photoswich detectors coupled to position sensitive photomultiplier tubes, giving a 4.8 cm axial field 
of view (FOV). A female Sprague-Dawley (SD) rat (207g) was provided with standard food and water 
ad libitum in a temperature and light-controlled environment. The animal was cannulated (Venisystem 
Butterfly, Abbott Ireland) in the tail vein for tracer injection under general anaesthesia with isoflurane 
(IsoFlo 100% w/w, Abbott Laboratories Ltd) 2.5 % (2 L min-1 oxygen flow). At the start of the scan 
[18F]-LCATD 4c (5.89 MBq) was injected as a single bolus and the administered radioactivity was 
measured as net counts in the cannula before and after the injection with an ionization chamber 
(Capintec CRC-15PET; Ramsey, New Jersey). Emission scans in 3D list-mode were acquired for 30 
minutes (with a FOV encompassing part of the thorax and the intestine) followed by a 5 minutes CT 
scan. At the end of the imaging experiment, the animal was sacrificed under anaesthesia (neck 
dislocation).   
PET acquisitions were obtained with an energy window set to 250 - 700 keV and corrections for dead-
time, activity decay, attenuation, random and scatter counts were applied (using the manufacturer' 
software). The dynamic images were obtained by sorting the list mode data into the following time 
frames: 6x10s, 8x30s, 10x60s, 3x300s, and images were reconstructed with a FORE/2D-OSEM 
reconstruction algorithm (provided by the manufacturer). Sampling at shorter intervals during early 
time-points enabled to detect rapid increments of tracer uptake in the liver and intestine.  Longer time 
frames at later time-points from the injection time showed the amounts of uptake characteristic for 
the specific PET tracer. Regions of interest (ROIs) corresponding to abdominal aorta, liver and 
gastrointestinal tract were manually drawn using PMOD software (PMOD Technologies). The stomach 
was included in the gastrointestinal ROI to include the amount of bile that might have refluxed from 
the duodenum into the stomach. Due to the limited FOV of the PET scan - which was not enough to 
cover the lower intestine - in this PET study the activity in the bile might be underestimated. 
 
Appendix A. Supplementary data. 
Supplementary data related to this article (NMR spectra, configuration for the automated 
radiosynthesis and HPLC profile of [18F]4c, 3D image of the three ROIs used for analysis of the PET 
scans) can be found at: XXXXXXXXXXXXXXXXXXX. 
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